Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Christopher Ellison | M | 66 | 14 years | |
Thian Chew | M | - | 7 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ralph Craven | M | 73 |
CBio Ltd.
CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | 4 years |
Gregory Collier | M | - | 6 years | |
Craig Newton | M | - | 2 years | |
Bruce Albert Goulds | M | - | 10 years | |
James Brett Lochran Heading | M | 67 | 4 years | |
Michael Monsour | M | - |
CBio Ltd.
CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | 4 years |
Garner William | M | 58 | 1 years | |
Helen Cameron | F | - |
CBio Ltd.
CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | 1 years |
Peter Corr | M | 76 |
CBio Ltd.
CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | 4 years |
James Campbell | M | - | 7 years | |
Warren Stephen Brooks | M | - |
CBio Ltd.
CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | - |
David Raymond Teplitzky | M | - | 8 years | |
Trevor Alan Verran | M | - | 1 years | |
Ross Mangelsdorf | M | - |
CBio Ltd.
CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | - |
Christopher B. Ward | M | - | 2 years | |
Marcel Edward van de Velde | M | - | 1 years | |
Mitchell Glass | M | - | 7 years | |
Marcus Hugh Titley | M | - | - | |
Göran Albert Ando | M | 75 |
CBio Ltd.
CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | 4 years |
Seth Yakatan | M | 53 | 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
Australia | 22 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Warren Thomas Brown
- Personal Network